Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …

…, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi… - The lancet …, 2014 - thelancet.com
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung …

…, LZ Lin, J Feng, Z Wang, Y Shu, J Shi… - The Lancet …, 2021 - thelancet.com
Background Immunotherapy combined with chemotherapy has been shown to be efficacious
as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without …

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label …

…, YL Wu, SY Wang, J Hu, W Liu, W Li, JH Shi - The Lancet …, 2018 - thelancet.com
Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …

[PDF][PDF] Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

…, J Yao, Y Zhang, M Li, J Feng, S Yang, Y Fan, J Shi… - Cancer cell, 2022 - cell.com
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping …

…, Y Cheng, L Jiang, N Yang, Z Han, J Shi… - The Lancet …, 2021 - thelancet.com
Background Savolitinib is a selective MET tyrosine-kinase inhibitor. We investigated the activity
and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other non…

Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized …

…, H Sun, G Wen, Y Ji, M Dvorkin, J Shi, Z Pan, J Shi… - Jama, 2022 - jamanetwork.com
Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …

Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …

…, L Zhang, J Shi, Z Wang, Y Cheng, J He, Y Shi… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in …

…, C Zhu, Z Ma, J Fang, G Chen, J Zhao, A Shi… - The Lancet …, 2022 - thelancet.com
Background A substantial proportion of patients with unresectable stage III non-small-cell
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …

[HTML][HTML] Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial …

…, HX Huang, Y Chen, GH Dai, JH Shi… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal
carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers …

[HTML][HTML] AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon–small-cell lung cancer with …

S Lu, X Dong, H Jian, J Chen, G Chen… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind …